Duavee

Chemical Nameconjugated estrogens/bazedoxifene
Dosage FormTablet (oral; 0.45 mg conjugated estrogens and 20 mg bazedoxifene)
Drug ClassHormones
SystemFemale reproductive
CompanyPfizer
Approval Year2013

Indication

  • For the treatment of moderate to severe vasomotor symptoms associated with menopause.
  • Indicated for the prevention of postmenopausal osteoporosis.
Last updated on 6/23/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Duavee (conjugated estrogens/bazedoxifene) Prescribing Information.2019Wyeth Pharmaceuticals Inc., Philadelphia PA
Document TitleYearSource
Australian public assessment report for conjugated estrogens / bazedoxifene acetate. 2018Australian Government: Department of Health
Document TitleYearSource
The 2017 hormone therapy position statement of the North American Menopause Society.2017The Journal of The North American Menopause Society